


DENVER (October 3, 2008)—Aurora-based medical device company ValveXchange Inc. announced today that it has been awarded a European patent (EP1,671,608) entitled Cardiovascular Valve Assembly, authored by Dr. Ivan Vesely, the company's Founder and Chief Scientific Officer. The patent has very broad claims on the company's exchangeable valve technology, protecting its two-part exchangeable valve in Europe. An image taken from the granted patent is shown below. This European Patent is now the 4th in a growing portfolio of issued [patents](#) held by ValveXchange Inc.



ValveXchange holds patented technology on a novel approach to the construction of bioprosthetic heart valves which will allow them to provide lifetime service without anti-coagulation therapy. ValveXchange is currently initiating private equity financing to bring its technology to the clinical trial stage.

About ValveXchange, Inc.: ValveXchange is a Delaware C Corporation headquartered in Aurora, Colorado developing a proprietary two-piece bioprosthetic heart valve for patients suffering from heart valve disease. The company was founded by Ivan Vesely, PhD, an internationally recognized expert in heart valve research. The company is lead by Chairman and CEO Larry Blankenship, a highly experienced medical device industry leader and serial entrepreneur. ValveXchange does not yet have FDA or any other approvals for its products, which are in a research and development stage. More information is available on the company's website: [www.valvexchange.com](http://www.valvexchange.com).